Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Freegold Intersects 3.62 g/t Au over 42m and 1.23 g/t Au over 170.7m (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

GB Group Ord Shs GBGPF

Healthcare Technology Drug Manufacturers - Specialty & Generic Software - Application Cannabis
GB Group plc is a United Kingdom-based company, which provides identity data intelligence products and services helping organizations recognize and verify all elements of an individual's identity at key interactions in their business processes. The Company's segments include location, identity and fraud. The location segment includes address lookup, verification and capture; e-mail validation; phone verification, and data maintenance services. The identity segment includes document verification, data verification and identity investigation services. Its identity verification solutions can be configured to carry out a wide range of functions, including know your customer checks, anti-money laundering checks, age verification checks and liveness detection. The fraud segment includes transaction fraud monitoring, combating origination fraud and in-life fraud investigation services. It provides artificial intelligence powered screening for automatic onboarding or referral of customers.


OTCPK:GBGPF - Post by User

GB Group Ord Shs > Either ACB pays $28 to $30 per share for CMED or...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by Interpolation2on Dec 26, 2017 5:33pm
227 Views
Post# 27227648

RE:RE:RE:RE:Either ACB pays $28 to $30 per share for CMED or...

RE:RE:RE:RE:Either ACB pays $28 to $30 per share for CMED or...I sold my CMED late last week.  Only two options in play were two pay a large dilutive premium for HIP and inherit its obligations or reveive at most $24 but not in cash but rather in shares of ACB.  It is little wonder CMED shares are stuck while other company share prices are ramping up at warp speed.  This is not a criticism of CMED etc ... not at all.  It is just the bear trap the share price is caught in at this time  due to the nature of the ACB offer and the nature of the 1st CMED  posion pill (HIP takeover) ....  :(

Peace13 wrote: thorgb1  ...  just sad!  Seems you are in deep denial.  And angry.  You and Dogger.  

Nothing wrong with CanniMed as a company but some of the investors show how out of touch some CMED people are about the new MJ industry.
Stop taking it so personal, it is business.
Joining ACB is the best thing to happen to CMED and its investors.    


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities